You just read:

Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy

News provided by

Benitec Biopharma Limited

Jan 16, 2018, 08:00 ET